Transthyretin Amyloid Cardiomyopathy Treatment MarketSize and Trends

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% during the forecast period (2023-2030).

The market is expected to witness significant growth over the forecast period driven by increasing diagnosis rates and the approval of novel therapies for ATTR-CM. Tafamidis is the leading treatment option and its label expansion to later-stage patients is expected to drive the market growth over the forecast period. . Medicines like patisiran and inotersen that received recent U.S. Food and Drug Administration (FDA) approvals for a related indication like, polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR), could also be tested for treatment of ATTR-CM, and can contribute to market growth. However, being an orphan disease, patient population is small and concentrated in certain regions like Europe and Japan which make trials and commercialization efforts more difficult.

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market– Market Trends

Increasing diagnosis of ATTR-CM: Due to advancements in echocardiography and cardiac MRI techniques, doctors can more accurately diagnose ATTR-CM. Earlier, ATTR-CM was difficult to differentiate from other cardiomyopathies based on symptoms alone. However, new technologies like nuclear scintigraphy imaging using radioisotope tracers that target misfolded amyloid proteins in the heart have drastically improved diagnosis rates. In April 2023, according to an article published by StatPearls, a professional healthcare education and technology company, non-invasive cardiac imaging like cardiac MRI and bone avid scintigraphy contribute significantly in diagnosis of ATTR-CM. Doctors are also learning to recognize vague but characteristic echocardiogram findings which help in diagnosis of ATTR-CM. The improved understanding of the disease manifestations, combined with better diagnostic tools have allowed identification of many cases that were previously overlooked or misdiagnosed. As more patients receive an accurate ATTR-CM diagnosis, the eligible patient pool for disease modifying therapies will naturally expand in the near future.
Growing elderly population: Growing elderly population demographic is major driver of the market as more patients will need therapy over time. In January 2023, according to the World Social Report 2023 published by United Nations, the number of people aged 65 and older globally is expected to be more than double from 2021 to 2050. The number of people aged 65 years or above is estimated increase from 761 Mn in 2021 to 1.6 Bn in 2050. Moreover, the oldest old population (persons aged 80 years or over) is the fastest growing segment of the world’s population. ATTR-CM primarily affects the elderly, and its prevalence increases significantly with age. The rare form caused by mutations early-onset whereas the more common wild-type ATTR-CM usually occurs after age 65 years. With substantial growth in the numbers of aging population globally, the pool of individuals at high risk of developing age-related amyloidosis and ATTR-CM will expand rapidly, and thus, creating an upward pressure on disease incidence rates in the near future.

North America is expected to be the dominant market due topresence of supportive patient assistance programs and greater awareness levels about ATTR-CM among physicians. Europe is also a sizable contributor while Japan with an aging population, is expected to witness fastest growth. Development of diagnostic tools and encouraging collaborations between biopharma companies and advocacy groups will be the key to boosting the market potential further.

Key Trends: Increasing adoption of inorganic growth strategies by key market players: Increasing adoption of inorganic growth strategies such as acquisition and merger by the key market players is a prominent trend in the market. For instance, in July 2021, Eidos Therapeutics, a clinical-stage biotech company, was acquired by BridgeBio Pharma, a commercial-stage biopharmaceutical company. This acquisition accelerated BridgeBio's development of its investigational therapy for the treatment of ATTR-CM, AG10. The acquisition expanded BridgeBio's pipeline of therapies for rare and other diseases